IC
CLYM

Ikarian Capital’s Climb Bio CLYM Stock Holding History

Ikarian Capital’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-175,088
Closed -$214K – 194
2025
Q1 		$214K Hold
175,088
– – 0.03% 137
2024
Q4 		$315K Sell
175,088
-12
-0% -$43 0.04% 142
2024
Q3 		$891K Buy
175,100
+75,100
+75% +$531K 0.12% 100
2024
Q2 		$711K Buy
+100,000
New +$666K 0.12% 85

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

Ikarian Capital's CLYM Position: Q2 2025 in Review

Ikarian Capital sold out of Climb Bio (CLYM) in Q2 2025, closing a stake of 175,088 shares — an estimated $214K sold.

Ikarian Capital first reported a position in CLYM in Q2 2024 and held it in 4 quarters. The position peaked at $891K in Q3 2024. 69 funds tracked by Wall St. Rank hold CLYM as of Q2 2025.

  • Ikarian Capital reported no remaining Climb Bio position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 175,088 Climb Bio shares in Q2 2025, an estimated $214K.
  • Ikarian Capital first reported a position in Climb Bio in Q2 2024 and held it in 4 quarters.
  • Ikarian Capital's Climb Bio position peaked at $891K in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Climb Bio as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.